Usefulness of vonoprazan,a potassium ion-competitive acid blocker,for primary eradication of Helicobacter pylori

被引:8
|
作者
Shinya Yamada [1 ]
Takumi Kawakami [1 ]
Yoshikazu Nakatsugawa [1 ]
Takahiro Suzuki [1 ]
Hideki Fujii [1 ]
Naoya Tomatsuri [1 ]
Hideki Nakamura [1 ]
Hideki Sato [1 ]
Yusuke Okuyama [1 ]
Hiroyuki Kimura [1 ]
Norimasa Yoshida [1 ]
机构
[1] Department of Gastroenterology,Japanese Red Cross Kyoto Daiichi Hospital
关键词
Helicobacter pylori; Eradication; Vonoprazan; Chronic gastritis; Potassium ion-competitive acid blocker;
D O I
暂无
中图分类号
R573 [胃疾病];
学科分类号
1002 ; 100201 ;
摘要
AIM To investigate usefulness of triple therapy with vonoprazan,a potassium ion-competitive acid blocker and antibiotics,for Helicobacter pylori(H.pylori) eradication.METHODS The H.pylori eradication rate was examined in 2507 patients(2055 undergoing primary eradication and 452 undergoing secondary eradication,excluding patients with subtotal gastrectomy) at the Japanese Red Cross Kyoto Daiichi Hospital from March 2013 to September 2015.For patients treated from March 2013 to February 2015,a proton pump inhibitor(PPI) was used to reduce acid secretion,while vonoprazan was used after March 2015.The success rates of the 2 regimens(PPI + amoxicillin + clarithromycin/metronidazole,or vonoprazan + amoxicillin + clarithromycin/metronidazole) were compared.RESULTS The success rate of primary H.pylori eradication was significantly higher in the vonoprazan group.When stratified by the underlying disease,a significant increase of the H.pylori eradication rate was observed in patients with chronic gastritis.A significantly lower H.pylori eradication rate was observed in younger patients compared to older patients in the PPI group,but there was no difference according to age in the vonoprazan group.On the otherhand,the success rate of secondary eradication was similar at approximately 90% in both groups.CONCLUSION Vonoprazan is very useful for primary eradication of H.pylori,and may become a first-line acid secretion inhibitor instead of PPIs.
引用
收藏
页码:550 / 555
页数:6
相关论文
共 50 条
  • [21] Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication
    Kusunoki, Maho
    Yuki, Mika
    Ishitobi, Hitomi
    Kobayashi, Yoshiya
    Nagaoka, Makoto
    Takahashi, Yoshiko
    Fukuba, Nobuhiko
    Komazawa, Yoshinori
    Shizuku, Toshihiro
    Kinoshita, Yoshikazu
    INTERNAL MEDICINE, 2019, 58 (11) : 1549 - 1555
  • [22] Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438)
    Otake, Kazuyoshi
    Sakurai, Yuuichi
    Nishida, Haruyuki
    Fukui, Hideo
    Tagawa, Yoshihiko
    Yamasaki, Hitomi
    Karashima, Masatoshi
    Otsuka, Keiichi
    Inatomi, Nobuhiro
    ADVANCES IN THERAPY, 2016, 33 (07) : 1140 - 1157
  • [23] Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438)
    Kazuyoshi Otake
    Yuuichi Sakurai
    Haruyuki Nishida
    Hideo Fukui
    Yoshihiko Tagawa
    Hitomi Yamasaki
    Masatoshi Karashima
    Keiichi Otsuka
    Nobuhiro Inatomi
    Advances in Therapy, 2016, 33 : 1140 - 1157
  • [24] Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori
    Shinozaki, Satoshi
    Nomoto, Hiroaki
    Kondo, Yoshie
    Sakamoto, Hirotsugu
    Hayashi, Yoshikazu
    Yamamoto, Hironori
    Lefor, Alan Kawarai
    Osawa, Hiroyuki
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2016, 32 (05) : 255 - 260
  • [25] Effect of Concomitant Use of Polaprezinc and Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication
    Suzuki, Yuto
    Katayama, Yasumi
    Fujimoto, Yo
    Toyoda, Koji
    Takahashi, Morio
    Tamano, Masaya
    GASTROENTEROLOGY INSIGHTS, 2024, 15 (02) : 386 - 395
  • [26] Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy
    Sakurai, Kouichi
    Suda, Hiroko
    Ido, Yumi
    Takeichi, Takayuki
    Okuda, Ayako
    Hasuda, Kiwamu
    Hattori, Masahiro
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (04) : 668 - 675
  • [27] Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy
    Kouichi Sakurai
    Hiroko Suda
    Yumi Ido
    Takayuki Takeichi
    Ayako Okuda
    Kiwamu Hasuda
    Masahiro Hattori
    World Journal of Gastroenterology, 2017, (04) : 668 - 675
  • [28] Potassium-competitive acid blockers: rethinking acid suppression for gastroesophageal reflux disease and Helicobacter pylori
    Antequera, Carol M.
    Orleck, Kimberly
    Jacob, Rinu
    Kenneally, Amy
    Wright, Wendy L.
    POSTGRADUATE MEDICINE, 2024, 136 (02) : 131 - 140
  • [29] Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance
    Hiroshi Matsumoto
    Akiko Shiotani
    Ryo Katsumata
    Minoru Fujita
    Rui Nakato
    Takahisa Murao
    Manabu Ishii
    Tomoari Kamada
    Ken Haruma
    David Y. Graham
    Digestive Diseases and Sciences, 2016, 61 : 3215 - 3220
  • [30] Efficacy of Helicobacter pylori eradication with vonoprazan-based triple therapy
    Noda, Hiroto
    Goto, Osamu
    Koizumi, Eriko
    Agawa, Shuhei
    Ikeda, Go
    Higuchi, Kazutoshi
    Akimoto, Teppei
    Yamawaki, Hiroshi
    Kodaka, Yasuhiro
    Ueki, Nobue
    Futagami, Seiji
    Fujimori, Shunji
    Kaise, Mitsuru
    Iwakiri, Katsuhiko
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 364 - 364